A Phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of SION-719 in healthy participants
Latest Information Update: 10 Nov 2025
At a glance
- Drugs SION 719 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Sionna Therapeutics
Most Recent Events
- 24 Oct 2025 According to a Sionna Therapeutics media release, company presented data from this study at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington October 22-25.
- 24 Oct 2025 Results presented in the Sionna Therapeutics media release.
- 21 Oct 2025 Results presented in the Sionna Therapeutics Media Release.